Skip to main content
Top
Published in: BMC Psychiatry 1/2013

Open Access 01-12-2013 | Research article

Conformance to schizophrenia treatment guidelines in North West-Bank, Palestine: focus on antipsychotic dosing and polytherapy

Authors: Waleed M Sweileh, Jihad Bani Odeh, Sa’ed H Zyoud, Ansam F Sawalha, Manal S Ihbeasheh

Published in: BMC Psychiatry | Issue 1/2013

Login to get access

Abstract

Background

Analysis of the prescribing patterns of antipsychotic drugs can improve therapeutic outcomes. The purpose of this study was to evaluate the prescribing pattern of antipsychotics and its conformance to international treatment guidelines.

Methods

A cross sectional study at primary psychiatric centers was carried out. Patients’ medical files were used to obtain demographic, medication and clinical information. International guidelines for schizophrenia were used to create conformance indicators. All statistical analyses were conducted using Statistical Package for Social Sciences.

Results

250 patients were included in this study. A total of 406 antipsychotic agents were used; 348 (85.7%) were first generation antipsychotics (FGA). The prevalence of antipsychotic combination was 50.4% (n=126). There was no significant difference in positive (p=0.3), negative (p=0.06) and psychopathology (p=0.5) scores of schizophrenia symptoms among patients on monotherapy versus those on antipsychotic combination. Furthermore, no significant difference was observed in the annual cost of antipsychotic monotherapy versus combination therapy. One hundred and five patients (42%) were using optimum dose of (300 – 600 mg CPZeq) while the remaining were using sub or supra therapeutic doses. Analysis showed that use of depot, use of anticholinergic agents and increasing amount of total CPZeq were significant factors associated with antipsychotic combination.

Conclusions

This study indicated that antipsychotic prescribing was not in conformance with international guidelines with respect to maintenance dose and combination therapy. Type of antipsychotic treatment regimen, combination versus monotherapy, was not associated with better clinical or economic outcome.
Literature
2.
go back to reference Jaalouk D, Okasha A, Salamoun MM, Karam EG: Mental health research in the Arab world. Soc Psychiatry Psychiatr Epidemiol. 2012, 47 (11): 1727-1731. 10.1007/s00127-012-0487-8.CrossRefPubMed Jaalouk D, Okasha A, Salamoun MM, Karam EG: Mental health research in the Arab world. Soc Psychiatry Psychiatr Epidemiol. 2012, 47 (11): 1727-1731. 10.1007/s00127-012-0487-8.CrossRefPubMed
3.
go back to reference Gaebel W, Weinmann S, Sartorius N, Rutz W, McIntyre JS: Schizophrenia practice guidelines: international survey and comparison. Br J Psychiatry. 2005, 187: 248-255. 10.1192/bjp.187.3.248.CrossRefPubMed Gaebel W, Weinmann S, Sartorius N, Rutz W, McIntyre JS: Schizophrenia practice guidelines: international survey and comparison. Br J Psychiatry. 2005, 187: 248-255. 10.1192/bjp.187.3.248.CrossRefPubMed
4.
go back to reference APA: Practice guideline for the treatment of patients with schizophrenia. American psychiatric association. Am J Psychiatry. 1997, 154 (4 Suppl): 1-63. APA: Practice guideline for the treatment of patients with schizophrenia. American psychiatric association. Am J Psychiatry. 1997, 154 (4 Suppl): 1-63.
5.
go back to reference Lehman AF, Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB, Goldberg R, Green-Paden LD, Tenhula WN, Boerescu D, Tek C, et al: The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr Bull. 2004, 30 (2): 193-217. 10.1093/oxfordjournals.schbul.a007071.CrossRefPubMed Lehman AF, Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB, Goldberg R, Green-Paden LD, Tenhula WN, Boerescu D, Tek C, et al: The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr Bull. 2004, 30 (2): 193-217. 10.1093/oxfordjournals.schbul.a007071.CrossRefPubMed
6.
go back to reference Moore TA, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML, Essock SM, Finnerty M, Marder SR, Miller DD, et al: The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry. 2007, 68 (11): 1751-1762. 10.4088/JCP.v68n1115.CrossRefPubMed Moore TA, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML, Essock SM, Finnerty M, Marder SR, Miller DD, et al: The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry. 2007, 68 (11): 1751-1762. 10.4088/JCP.v68n1115.CrossRefPubMed
7.
go back to reference Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, et al: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005, 353 (12): 1209-1223. 10.1056/NEJMoa051688.CrossRefPubMed Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, et al: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005, 353 (12): 1209-1223. 10.1056/NEJMoa051688.CrossRefPubMed
8.
go back to reference Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW: Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006, 63 (10): 1079-1087. 10.1001/archpsyc.63.10.1079.CrossRefPubMed Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW: Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006, 63 (10): 1079-1087. 10.1001/archpsyc.63.10.1079.CrossRefPubMed
9.
go back to reference NICE: National Institute for Health and Care Excellence. CG 82. 2011, Schizophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care (update), http://www.nice.org.uk/CG82 (accessed 27 March 2013) NICE: National Institute for Health and Care Excellence. CG 82. 2011, Schizophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care (update), http://​www.​nice.​org.​uk/​CG82 (accessed 27 March 2013)
10.
go back to reference Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR, et al: The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2009, 36 (1): 71-93.CrossRefPubMedPubMedCentral Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR, et al: The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2009, 36 (1): 71-93.CrossRefPubMedPubMedCentral
11.
go back to reference Woods SW: Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003, 64 (6): 663-667. 10.4088/JCP.v64n0607.CrossRefPubMed Woods SW: Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003, 64 (6): 663-667. 10.4088/JCP.v64n0607.CrossRefPubMed
12.
go back to reference Xiang YT, Weng YZ, Leung CM, Tang WK, Ungvari GS: Clinical and social correlates with the use of depot antipsychotic drugs in outpatients with schizophrenia in China. Int J Clin Pharmacol Ther. 2008, 46 (5): 245-251.CrossRefPubMed Xiang YT, Weng YZ, Leung CM, Tang WK, Ungvari GS: Clinical and social correlates with the use of depot antipsychotic drugs in outpatients with schizophrenia in China. Int J Clin Pharmacol Ther. 2008, 46 (5): 245-251.CrossRefPubMed
13.
go back to reference Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987, 13 (2): 261-276. 10.1093/schbul/13.2.261.CrossRefPubMed Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987, 13 (2): 261-276. 10.1093/schbul/13.2.261.CrossRefPubMed
14.
go back to reference Kay SR, Opler LA, Lindenmayer JP: Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res. 1988, 23 (1): 99-110. 10.1016/0165-1781(88)90038-8.CrossRefPubMed Kay SR, Opler LA, Lindenmayer JP: Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res. 1988, 23 (1): 99-110. 10.1016/0165-1781(88)90038-8.CrossRefPubMed
15.
go back to reference Adeponle AB, Obembe AO, Adeyemi SO, Suleiman GT: Polypharmacy in psychiatric out-patient practice in northern Nigeria. Afr J Psychiatry (Johannesbg). 2007, 10 (4): 215-218. Adeponle AB, Obembe AO, Adeyemi SO, Suleiman GT: Polypharmacy in psychiatric out-patient practice in northern Nigeria. Afr J Psychiatry (Johannesbg). 2007, 10 (4): 215-218.
16.
go back to reference Koen L, Magni P, Niehaus DJ, le Roux A: Antipsychotic prescription patterns in Xhosa patients with schizophrenia or schizoaffective disorder. Afr J Psychiatry (Johannesbg). 2008, 11 (4): 287-290. Koen L, Magni P, Niehaus DJ, le Roux A: Antipsychotic prescription patterns in Xhosa patients with schizophrenia or schizoaffective disorder. Afr J Psychiatry (Johannesbg). 2008, 11 (4): 287-290.
17.
go back to reference Procyshyn RM, Kennedy NB, Tse G, Thompson B: Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution. Can J Psychiatry. 2001, 46 (4): 334-339.PubMed Procyshyn RM, Kennedy NB, Tse G, Thompson B: Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution. Can J Psychiatry. 2001, 46 (4): 334-339.PubMed
18.
go back to reference Procyshyn RM, Thompson B: Patterns of antipsychotic utilization in a tertiary care psychiatric institution. Pharmacopsychiatry. 2004, 37 (1): 12-17.CrossRefPubMed Procyshyn RM, Thompson B: Patterns of antipsychotic utilization in a tertiary care psychiatric institution. Pharmacopsychiatry. 2004, 37 (1): 12-17.CrossRefPubMed
19.
go back to reference Ramadas S, Kuttichira P, Sumesh TP, Ummer SA: A study of an antipsychotic prescription pattern of patients with schizophrenia in a developing country. Indian J Psychol Med. 2010, 32 (1): 13-16. 10.4103/0253-7176.70520.CrossRefPubMedPubMedCentral Ramadas S, Kuttichira P, Sumesh TP, Ummer SA: A study of an antipsychotic prescription pattern of patients with schizophrenia in a developing country. Indian J Psychol Med. 2010, 32 (1): 13-16. 10.4103/0253-7176.70520.CrossRefPubMedPubMedCentral
20.
go back to reference Xiang YT, Weng YZ, Leung CM, Tang WK, Ungvari GS: Clinical and social determinants of antipsychotic polypharmacy for chinese patients with shizophrenia. pharmocopsychitry. 2007, 40: 47-52. 10.1055/s-2007-970062.CrossRef Xiang YT, Weng YZ, Leung CM, Tang WK, Ungvari GS: Clinical and social determinants of antipsychotic polypharmacy for chinese patients with shizophrenia. pharmocopsychitry. 2007, 40: 47-52. 10.1055/s-2007-970062.CrossRef
21.
go back to reference Satake N, Hazama K, Sono T, Takahashi M, Ito J: Changes in antipsychotic medication in clients of assertive community treatment in Japan: a one-year follow up. Clin Pract Epidemiol Ment Health. 2011, 19 (7): 1-3. Satake N, Hazama K, Sono T, Takahashi M, Ito J: Changes in antipsychotic medication in clients of assertive community treatment in Japan: a one-year follow up. Clin Pract Epidemiol Ment Health. 2011, 19 (7): 1-3.
22.
go back to reference Xiang Y, Weng Y, Leung C, Tang W, Ungvari G: Clinical and social determinants of antipsychotic polypharmacy for Chinese patients with schizophrenia. Pharmacopsychiatry. 2007, 40 (2): 47-52. 10.1055/s-2007-970062.CrossRefPubMed Xiang Y, Weng Y, Leung C, Tang W, Ungvari G: Clinical and social determinants of antipsychotic polypharmacy for Chinese patients with schizophrenia. Pharmacopsychiatry. 2007, 40 (2): 47-52. 10.1055/s-2007-970062.CrossRefPubMed
23.
go back to reference Ganguly R, Kotzan J, Miller L, Kennedy K, Martin B: Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998–2000. J Clin Psychiatry. 2004, 65 (10): 1377-1388. 10.4088/JCP.v65n1013.CrossRefPubMed Ganguly R, Kotzan J, Miller L, Kennedy K, Martin B: Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998–2000. J Clin Psychiatry. 2004, 65 (10): 1377-1388. 10.4088/JCP.v65n1013.CrossRefPubMed
24.
go back to reference Sim K, Su A, Fujii S, Yang SY, Chong MY, Ungvari GS, Si T, Chung EK, Tsang HY, Chan YH, et al: Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. Br J Clin Pharmacol. 2004, 58 (2): 178-183. 10.1111/j.1365-2125.2004.02102.x.CrossRefPubMedPubMedCentral Sim K, Su A, Fujii S, Yang SY, Chong MY, Ungvari GS, Si T, Chung EK, Tsang HY, Chan YH, et al: Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. Br J Clin Pharmacol. 2004, 58 (2): 178-183. 10.1111/j.1365-2125.2004.02102.x.CrossRefPubMedPubMedCentral
25.
go back to reference Taylor DMS, Mace S, Whiskey E: Co-prescribing of atypical and typical antipsychotics - prescribing sequence and documented outcome. Psychiatr Bull. 2002, 26: 170-2. 10.1192/pb.26.5.170.CrossRef Taylor DMS, Mace S, Whiskey E: Co-prescribing of atypical and typical antipsychotics - prescribing sequence and documented outcome. Psychiatr Bull. 2002, 26: 170-2. 10.1192/pb.26.5.170.CrossRef
26.
go back to reference Correll CU, Frederickson AM, Kane JM, Manu P: Does antipsychotic polypharmacy increase the risk for metabolic syndrome?. Schizophr Res. 2007, 89 (1–3): 91-100.CrossRefPubMed Correll CU, Frederickson AM, Kane JM, Manu P: Does antipsychotic polypharmacy increase the risk for metabolic syndrome?. Schizophr Res. 2007, 89 (1–3): 91-100.CrossRefPubMed
27.
go back to reference Honer W, Thornton A, Chen E, Chan R, Wong J, Bergmann A, Falkai P, Pomarol-Clotet E, McKenna P, Stip E, et al: Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med. 2006, 354 (5): 472-482. 10.1056/NEJMoa053222.CrossRefPubMed Honer W, Thornton A, Chen E, Chan R, Wong J, Bergmann A, Falkai P, Pomarol-Clotet E, McKenna P, Stip E, et al: Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med. 2006, 354 (5): 472-482. 10.1056/NEJMoa053222.CrossRefPubMed
28.
go back to reference Shim J, Shin J, Kelly D, Jung D, Seo Y, Liu K, Shon J, Conley R: Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry. 2007, 164 (9): 1404-1410. 10.1176/appi.ajp.2007.06071075.CrossRefPubMed Shim J, Shin J, Kelly D, Jung D, Seo Y, Liu K, Shon J, Conley R: Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry. 2007, 164 (9): 1404-1410. 10.1176/appi.ajp.2007.06071075.CrossRefPubMed
29.
go back to reference Agelink M, Kavuk I, Ak I: Clozapine with amisulpride for refractory schizophrenia. Am J Psychiatry. 2004, 161 (5): 924-925.CrossRefPubMed Agelink M, Kavuk I, Ak I: Clozapine with amisulpride for refractory schizophrenia. Am J Psychiatry. 2004, 161 (5): 924-925.CrossRefPubMed
30.
go back to reference Kreyenbuhl JA, Valenstein M, McCarthy JF, Ganoczy D, Blow FC: Long-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns. Psychiatr Serv. 2007, 58 (4): 489-495. 10.1176/appi.ps.58.4.489.CrossRefPubMedPubMedCentral Kreyenbuhl JA, Valenstein M, McCarthy JF, Ganoczy D, Blow FC: Long-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns. Psychiatr Serv. 2007, 58 (4): 489-495. 10.1176/appi.ps.58.4.489.CrossRefPubMedPubMedCentral
31.
go back to reference Chakos MH, Glick ID, Miller AL, Hamner MB, Miller DD, Patel JK, Tapp A, Keefe RS, Rosenheck RA: Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatr Serv. 2006, 57 (8): 1094-1101. 10.1176/appi.ps.57.8.1094.CrossRefPubMed Chakos MH, Glick ID, Miller AL, Hamner MB, Miller DD, Patel JK, Tapp A, Keefe RS, Rosenheck RA: Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatr Serv. 2006, 57 (8): 1094-1101. 10.1176/appi.ps.57.8.1094.CrossRefPubMed
32.
go back to reference Hong I, Bishop J: Anticholinergic use in children and adolescents after initiation of antipsychotic therapy. Ann Pharmacother. 2010, 44 (7–8): 1171-1180.CrossRefPubMedPubMedCentral Hong I, Bishop J: Anticholinergic use in children and adolescents after initiation of antipsychotic therapy. Ann Pharmacother. 2010, 44 (7–8): 1171-1180.CrossRefPubMedPubMedCentral
33.
go back to reference Xiang Y, Wang C, Si T, Lee E, He Y, Ungvari G, Chiu H, Yang S, Chong M, Tan C, et al: Use of anticholinergic drugs in patients with schizophrenia in Asia from 2001 to 2009. Pharmacopsychiatry. 2011, 44 (3): 114-118. 10.1055/s-0031-1275658.CrossRefPubMed Xiang Y, Wang C, Si T, Lee E, He Y, Ungvari G, Chiu H, Yang S, Chong M, Tan C, et al: Use of anticholinergic drugs in patients with schizophrenia in Asia from 2001 to 2009. Pharmacopsychiatry. 2011, 44 (3): 114-118. 10.1055/s-0031-1275658.CrossRefPubMed
34.
go back to reference Lehman AF, Steinwachs DM: Patterns of usual care for schizophrenia: initial results from the Schizophrenia Patient Outcomes Research Team (PORT) Client Survey. Schizophr Bull. 1998, 24 (1): 11-20. 10.1093/oxfordjournals.schbul.a033303. discussion 20–32CrossRefPubMed Lehman AF, Steinwachs DM: Patterns of usual care for schizophrenia: initial results from the Schizophrenia Patient Outcomes Research Team (PORT) Client Survey. Schizophr Bull. 1998, 24 (1): 11-20. 10.1093/oxfordjournals.schbul.a033303. discussion 20–32CrossRefPubMed
35.
go back to reference Chen RS, Nadkarni PM, Levin FL, Miller PL, Erdos J, Rosenheck RA: Using a computer database to monitor compliance with pharmacotherapeutic guidelines for schizophrenia. Psychiatr Serv. 2000, 51 (6): 791-794. 10.1176/appi.ps.51.6.791.CrossRefPubMed Chen RS, Nadkarni PM, Levin FL, Miller PL, Erdos J, Rosenheck RA: Using a computer database to monitor compliance with pharmacotherapeutic guidelines for schizophrenia. Psychiatr Serv. 2000, 51 (6): 791-794. 10.1176/appi.ps.51.6.791.CrossRefPubMed
36.
go back to reference Hayhurst K, Drake R, Lewis S: Patient factors associated with receipt of combination antipsychotic drug therapy in the treatment of schizophrenia. J Psychopharmacol. 2010, 24 (1): 83-89. 10.1177/0269881108095169.CrossRefPubMed Hayhurst K, Drake R, Lewis S: Patient factors associated with receipt of combination antipsychotic drug therapy in the treatment of schizophrenia. J Psychopharmacol. 2010, 24 (1): 83-89. 10.1177/0269881108095169.CrossRefPubMed
37.
go back to reference Barnes T, Paton C: Antipsychotic polypharmacy in schizophrenia: benefits and risks. CNS Drugs. 2011, 25 (5): 383-399. 10.2165/11587810-000000000-00000.CrossRefPubMed Barnes T, Paton C: Antipsychotic polypharmacy in schizophrenia: benefits and risks. CNS Drugs. 2011, 25 (5): 383-399. 10.2165/11587810-000000000-00000.CrossRefPubMed
Metadata
Title
Conformance to schizophrenia treatment guidelines in North West-Bank, Palestine: focus on antipsychotic dosing and polytherapy
Authors
Waleed M Sweileh
Jihad Bani Odeh
Sa’ed H Zyoud
Ansam F Sawalha
Manal S Ihbeasheh
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2013
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/1471-244X-13-179

Other articles of this Issue 1/2013

BMC Psychiatry 1/2013 Go to the issue